Dirk Hadaschik
Chief Scientific Officer Cecava
Dr Dirk Hadaschik is the Chief Scientific Officer at Cecava, where he leads the scientific and clinical development of personalised cancer vaccines. With a background in molecular biology and extensive experience in clinical research, he has played a key role in advancing neoepitope-based immunotherapies and co-invented proprietary algorithms for antigen selection. He previously held senior R&D and clinical leadership roles at CeGaT and Qiagen, contributing to the development of next-generation sequencing–based diagnostics and cancer treatment approaches.
Seminars
Thursday 23rd July 2026
Retrolective Analysis of Brain Tumour Patients Adding Personalised Neoantigen Peptide Treatment To Their Standard Therapy in a Real-World Setting
2:00 pm
- Neoantigen peptide immunization is well tolerated and induces durable T-cell responses in patients with difficult to treat brain tumours
- A diversified immune response to neoantigens significantly correlates with survival of immunized brain tumour patients
- Based on these experiences manufacturing workflows are optimized and clinical trials are designed
